Endocrine System Channel
Topics
Medications
Quicklinks
Related Channels

Precautions and Warnings With Rosiglitazone and Glimepiride

Some Rosiglitazone and Glimepiride Warnings and Precautions

Patients taking this drug should keep the following considerations in mind:
 
  • Some studies have suggested that rosiglitazone (one of the components of this medication) may increase the risk of heart attacks and other similar problems. However, other studies have not shown an increased risk. At this time, there is not enough evidence to know for sure if rosiglitazone actually increases the risk of heart attacks.

 

  • In studies, combining insulin with rosiglitazone appeared to increase the risk of problems such as congestive heart failure and heart attacks. In general, it is not recommended to combine rosiglitazone with any type of insulin. 

 

  • Oral diabetes drugs, including rosiglitazone and glimepiride, may increase the risk of death due to heart or blood vessel problems, compared to diabetes treatment with diet or insulin. This warning is based on one research study that looked at a diabetes medication similar to rosiglitazone and glimepiride. At this time, it is unclear how important this risk may be in people taking rosiglitazone and glimepiride.
     
  • Rosiglitazone can cause fluid retention (gaining of water weight, known medically as edema). For most people, this is not dangerous. However, fluid retention can be serious in people with congestive heart failure (CHF). It is possible for fluid retention to lead to heart failure, even in people who have no history of heart failure or any other heart disease. There may be an increased risk of edema or heart failure for people who combine this medication with insulin.
If you notice any of the following symptoms, contact your healthcare provider: unexplained weight gain (three to five pounds or more in a week); swelling of the ankles, feet, or legs; cough; or shortness of breath (see Symptoms of Congestive Heart Failure for more signs and symptoms).
  • If you are allergic to sulfonamides ("sulfa" medications), you may also be allergic to rosiglitazone and glimepiride. However, not everyone who has a sulfa allergy will be allergic to this drug. Be sure to let your healthcare provider know if you have a sulfa allergy.
     
  • This drug can cause low blood sugar (hypoglycemia) in some people. This has been more common in elderly people and in people with adrenal, pituitary, liver, or kidney problems -- as well as during fasting before surgery and after prolonged exercise. Low blood sugar symptoms may include irritability, trembling, cold sweats, or blurry vision, among other things (see Avandaryl and Blood Sugar for more information).

 

  • Rosiglitazone and glimepiride may increase the risk of fractures (broken bones) in women. These fractures are typically different than those seen in postmenopausal women with osteoporosis. In a recent study, women taking Avandia® (rosiglitazone) were more likely to have broken bones -- especially in the upper arm, hand, or foot. Since rosiglitazone is one of the components of rosiglitazone and glimepiride, women taking this drug may be at higher risk for broken bones. Other studies suggest that men taking rosiglitazone may also be at a higher risk for fractures.
     
  • Rosiglitazone and glimepiride cannot be used to treat type 1 diabetes or diabetic ketoacidosis (a life-threatening condition that may occur with uncontrolled diabetes). These conditions need to be treated with insulin.
     
  • There have been reports of this drug causing macular edema (a condition of the eye). Tell your healthcare provider if you have any vision changes.

 

  • Sulfonylurea medications (such as glimepiride) may cause a dangerous problem known as hemolytic anemia in people who have a genetic condition known as glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency). Other non-sulfonylurea medications may be better choices for such people. 

 

  • Rosiglitazone and glimepiride can cause weight gain. In studies, people taking rosiglitazone and glimepiride gained about four to seven pounds on average over 28 weeks (see Avandaryl and Weight Gain). Talk to your healthcare provider about rapid weight gain, as this may be a sign of fluid retention.
     
  • If you are a pre-menopausal woman who has infertility problems (due to a lack of ovulation), this drug may increase your chance of ovulation (and pregnancy). Talk to your healthcare provider about birth control options if you would like to avoid pregnancy while taking rosiglitazone and glimepiride.
     
  • This drug may cause increased liver enzymes. Very rarely, this has led to liver damage. It is recommended that liver enzymes be checked prior to starting rosiglitazone and glimepiride and they should be checked again periodically. Liver enzymes are checked using a blood test. Rosiglitazone and glimepiride should not be started in people with high liver enzymes. This drug should be stopped if liver enzymes increase and continue to stay high, as this may be a sign of liver damage.
     
  • Rosiglitazone and glimepiride can interact with certain medications (see Drug Interactions with Rosiglitazone and Glimepiride).
     
  • Rosiglitazone and glimepiride is considered a pregnancy Category C medication. This means that it may not be safe to use during pregnancy. Talk to your healthcare provider about the risks and benefits of using this drug during pregnancy (see Avandaryl and Pregnancy for more information).
     
  • It is not known if rosiglitazone and glimepiride passes through breast milk. Therefore, if you are breastfeeding or plan to start breastfeeding, be sure to talk with your healthcare provider about this.
     
  • Sulfonylurea medicines, such as glimepiride (one of the components of rosiglitazone and glimepiride), have been reported to increase sensitivity to the sun. Therefore, when going outdoors, try wearing long sleeves, pants, and a hat. Any exposed skin should be covered with sunscreen that is at least SPF 15.
     
Type 2 Diabetes: Fact or Fiction

Rosiglitazone and Glimepiride Drug Info

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.